Effect of adalimumab on the expression profile of genes encoding histamine receptors in keratinocyte

Adalimumab is an immunosuppressive drug that neutralizes the membrane and soluble form of tumor necrosis factor alpha (TNF-α). As a representative of anti-TNF-α inhibitors, it is used in the treatment of articular psoriasis, rheumatoid arthritis, and Crohn's disease. The aim of the study was to evaluate changes in the expression of genes encoding HRH1-4 receptors in human skin keratinocytes (HaCaT line) treated with bacterial lipopolysaccharide followed by adalimumab compared to the control culture. HaCaT was exposed to 1 ng / ml LPS for 8 hours and then to 8 µg / ml adalimumab for 2, 8 and 24 hours compared to the control culture. Molecular analysis included the determination of the microarray expression profile of the assessed genes, which was then validated with the quantitative real-time polymerase chain reaction preceded by reverse transcription (RTqPCR) method. Under conditions of induced inflammation -LPS, the concentration of HRH1-3 is significantly lower compared to control and increases with the addition of the drug (p <0.05). The highest concentration of HRH1 and HRH3 in keratinocyte cultures exposed to adalimumab was observed after 8 hours of incubation. HRH2 expression is also highest under the influence of adalimumab (p<0.05). We have shown that adalimumab influences the activity of the histaminergic system in skin keratinocytes in vitro. The complex nature of the histaminergic system was confirmed.